New immune weapons target advanced prostate cancer

NCT ID NCT05125016

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing new immunotherapy drugs for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. The goal is to find safe doses and see if these drugs, which aim to activate the body's own immune cells to attack cancer, can shrink tumors. The study will enroll about 370 participants and test the main drug alone or in combination with other immune-boosting drugs.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Atrium Health Levine Cancer Institute
RECRUITING

Charlotte, North Carolina, 28204, United States
Fox Chase Cancer Center
WITHDRAWN

Philadelphia, Pennsylvania, 19111, United States
Fox Chase Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19111, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Norton Cancer Institute
RECRUITING

Louisville, Kentucky, 40207, United States
Penn Medicine University of Pennsylvania Health System
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Roswell Park Cancer Institute
RECRUITING

Buffalo, New York, 14263, United States
Rutgers Cancer Institute of New Jersey
RECRUITING

New Brunswick, New Jersey, 08901, United States
Stanford University Medical Center - Blake Wilbur Drive
RECRUITING

Palo Alto, California, 94304, United States
The Ohio State University James Cancer Hospital
RECRUITING

Columbus, Ohio, 43210, United States
Thomas Jefferson University Hospital
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
University of Maryland Greenebaum Cancer Center
RECRUITING

Baltimore, Maryland, 21201, United States
Yale University Hospital
RECRUITING

New Haven, Connecticut, 06510, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER